Literature DB >> 2815938

[Giant cell tumor of bone. An analysis of 69 cases].

P Wuisman1, A Härle, B Nommensen, R Erlemann, M Reiser, A Rössner.   

Abstract

1. The tumor stage of the giant cell tumor is an indicator for the prognosis and the need for adjuvant therapy. 2. Intralesional excisions without an adjuvant result in high rates of recurrence. 3. Polymethyl methyl acrylate (PMMA) largely prevents recurrences, provides stability and makes early functional treatment possible. 4. Broad excisions should only be performed in bone which is dispensable. 5. Recurrences frequently manifest themselves by pain. They can be removed intralesionally, as in primary therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2815938     DOI: 10.1055/s-2008-1044684

Source DB:  PubMed          Journal:  Z Orthop Ihre Grenzgeb        ISSN: 0044-3220


  4 in total

Review 1.  Giant cell tumour of bone: a new evaluating system is necessary.

Authors:  Han Wang; Ningjun Wan; Yongcheng Hu
Journal:  Int Orthop       Date:  2012-10-05       Impact factor: 3.075

Review 2.  The impact of curettage technique on local control in giant cell tumour of bone.

Authors:  Gennady N Machak; Andrey I Snetkov
Journal:  Int Orthop       Date:  2020-10-22       Impact factor: 3.075

3.  Giant cell tumor of bone: treatment and outcome of 214 cases.

Authors:  Maurice Balke; Laura Schremper; Carsten Gebert; Helmut Ahrens; Arne Streitbuerger; Gabriele Koehler; Jendrik Hardes; Georg Gosheger
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-06       Impact factor: 4.553

4.  Curettage with cement augmentation of large bone defects in giant cell tumors with pathological fractures in lower-extremity long bones.

Authors:  Som P Gupta; Gaurav Garg
Journal:  J Orthop Traumatol       Date:  2016-02-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.